Recipharm: Strategic appointment

Contract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK and Ireland and driving sales of Recipharm’s manufacturing services.
Read more

Virbac: Managing global operations

French vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial strategies of the Group. 
Read more

Luminary in vaccine research

Jan Holmgren, developer of the first effective oral cholera vaccine, has been awarded the 2017 Sabin Gold Medal for his pioneering contributions to oral vaccine research and mucosal immunology, and his leadership in the discovery of the world’s first effective oral cholera vaccine.
Read more

Pharmalink: Launching into Phase III

Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
Read more

Metrion Biosciences: Developing the business

Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Read more

Gyros Protein Technologies: European Marketing

Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.

Read more

GenSight Biologics: Progressing the ophthalmic pipeline

Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.

Read more

Kymab: Track record in clinical development

Antibody developer Kymab Ltd has instated Sonia Quaratino as its first Chief Medical Officer. She will manage the clinical development of the Group’s expanding therapeutic antibody portfolio.

Read more

Oryzon Genomics: Taking on epigenetics

Biopharmaceutical company Oryzon Genomics has named Roger Bullock its Chief Medical Officer. He will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company.
Read more

GammaDelta Therapeutics: New at the top

London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
Read more